Business
Placing of Shares
Placing of Shares.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3074S\n SkinBioTherapeutics PLC\n 15 November 2021\n \n \n \n \n SkinBioTherapeutics plc\n \n (\"SkinBioTherapeutics\" or \"the Company\")\n \n \n Placing of shares held by major shareholder\n \n \n \n \n \n \n SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, has today been informed that its major shareholder, OptiBiotix Health Plc (\"OptiBiotix\") has placed 3,636,363 ordinary shares in SkinBioTherapeutics with new and existing institutional investors at a price of 55 pence per share. Prior to the sale OptiBiotix held 36,138,569 ordinary shares representing 23.1% of the Company and following this sale, will continue to hold 32,502,206 ordinary shares in SkinBioTherapeutics representing 20.7% of the Company.\n Optibiotix, Cenkos Securities Plc and the Company have entered into a lock-in and orderly market agreement pursuant to which Optibiotix has undertaken to the Company and to Cenkos that, subject to the customary exceptions: (i) it will not until the first anniversary of the sale dispose of the Ordinary Shares that it holds during such period; and (ii) it will only dispose of such Ordinary Shares during the 12 month period following such first anniversary through the Company's Nominated Adviser and Broker so as to ensure an orderly market in the Shares.\n \n Stuart Ashman, CEO of SkinBioTherapeutics, said:\n \n \n \"We are pleased that this placing is enabling us to bring in new institutional shareholders and broadening the shareholder base in an orderly fashion. The Company is going from strength to strength with its newly launched first commercial product, AxisBiotix-Ps™, so it is important to attract new investors who are keen to come on board to support us in the next stage of the Company's development, as a commercial entity.\"\n \n \n -Ends-\n \n \n For more information please contact:\n \n \n \n \n \n SkinBioTherapeutics plc\n Stuart J . Ashman, CEO\n Doug Quinn, CFO\n \n \n Tel: +44 (0) 161 468 2760\n \n \n \n \n \n Cenkos Securities Plc (Nominated Adviser & Broker)\n Giles Balleny, Max Gould (Corporate Finance)\n Michael Johnson, Dale Bellis (Sales)\n \n \n Tel: +44 (0) 20 7397 8900\n \n \n \n \n Instinctif Partners (financial press)\n Melanie Toyne-Sewell / Nathan Billis \n \n \n Tel: +44 (0) 20 7457 2020\n \n \n SkinBi...